To the full analysis
Buyback calculator for CorMedix
CorMedix stock: key metrics
CRMDCorMedix had an operating margin of 48.2% and a return on invested capital (ROIC) of 68.5% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2008 | no data | no data | no data |
| 2009 | no data | no data | no data |
| 2010 | no data | no data | no data |
| 2011 | no data | no data | no data |
| 2012 | no data | no data | no data |
| 2013 | −9,980.2% | −245,769.8% | −456,654.9% |
| 2014 | −135.5% | −4,703.3% | −10,806.3% |
| 2015 | −51.7% | −7,925.6% | −8,655.4% |
| 2016 | −63.6% | −11,048.8% | −10,996.5% |
| 2017 | 65.1% | −9,997.4% | −10,023.4% |
| 2018 | 7.7% | −6,250.4% | −6,242.4% |
| 2019 | −31.8% | −7,416.3% | −5,801.3% |
| 2020 | 14.4% | −11,378.4% | −9,207.7% |
| 2021 | 22.0% | −15,417.5% | −14,774.7% |
| 2022 | 94.3% | −46,819.9% | −45,409.9% |
| 2023 | no data | no data | no data |
| 2024 | 92.7% | −51.4% | −41.2% |
| 2025 | 88.5% | 48.2% | 52.3% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2008 | 74.8% | no data | −100.0% |
| 2009 | 55.2% | no data | −100.0% |
| 2010 | −100.0% | no data | −100.0% |
| 2011 | −100.0% | no data | −100.0% |
| 2012 | 200.0% | no data | −100.0% |
| 2013 | 200.0% | no data | −100.0% |
| 2014 | −100.0% | no data | −100.0% |
| 2015 | −53.5% | −69.8% | −49.0% |
| 2016 | −100.0% | −75.4% | −100.0% |
| 2017 | 21.7% | no data | −100.0% |
| 2018 | 15.0% | no data | −100.0% |
| 2019 | 8.4% | −95.6% | −55.8% |
| 2020 | −49.8% | −62.5% | −44.7% |
| 2021 | −44.9% | −42.8% | −40.9% |
| 2022 | −53.9% | −40.5% | −47.9% |
| 2023 | −66.1% | −61.2% | −56.5% |
| 2024 | −21.2% | −22.7% | −15.1% |
| 2025 | 40.2% | 68.5% | 19.7% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 31 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.